Novel Cancer Treatment From Georgia State Research and Da Zen Theranostics Advances to Next Stage of Clinical Trials
Novel Cancer Treatment From Georgia State Research and Da Zen Theranostics Advances to Next Stage of Clinical Trials
A Georgia State University startup company focused on developing cancer-fighting tools and treatments is making new strides by advancing its technology to the next phase of clinical trials.
Georgia State’s Office of Technology Transfer reports that Da Zen Theranostics is preparing an innovation known as DZ-002 for its next significant milestone, with Phase II clinical trials set to begin in early 2025.
Developed through Georgia State, Emory University and Cedars-Sinai Medical Center, DZ-002 aims to improve cancer patient survival rates and quality of life. This technology delivers anticancer drugs exclusively to cancer cells using a cancer-targeting dye carrier, and improves tumor diagnosis, detection and treatment by employing imaging dye-drug conjugates.